Abbott Laboratories: It's No Longer A Buy For Now
Abbott Laboratories is showing strong growth potential with rising sales and EPS, though slightly overvalued. See why we are ...
Abbott Labs Path To Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic
On Wednesday, Abbott Laboratories (NYSE:ABT) reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating ...
Abbott Laboratories posts Q3 beat, raises profit forecast
Abbott Laboratories (ABT) shares tick into positive territory in Wednesday's pre-market trading on its third quarter earnings ...
High-Quality Abbott Stock: Corporate Growth That Pays You to Own It
Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results ...
Crain's Chicago Business2d
Abbott Labs board OKs $7 billion stock buyback program
Medical device giant Abbott Laboratories is launching a $7 billion stock buyback program. The repurchase of common shares was ...
Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event
Abbott Laboratories' Q3 earnings and topline growth largely expected to be in line with the Q2 trend. Find out whether ABT ...
Yahoo Finance2d
Abbott Laboratories (ABT) Q3 2024 Earnings Call Transcript
Good day, and thank you for standing by. Welcome to Abbott's third quarter 2024 earnings conference call. [Operator instructions] This call is being recorded by Abbott. With the exception of any ...
Abbott Laboratories: Balanced Prospects Lead to Hold Recommendation Amid Market Adjustments
Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) today and set a price target ...